Written question asked by Greg Mulholland (Liberal Democrat) on Monday, 24 October 2016, in the House of Commons. It was due for an answer on Wednesday, 26 October 2016. It was answered by David Mowat (Conservative) on Monday, 31 October 2016 on behalf of the Department of Health.
Ataluren
- Question
-
To ask the Secretary of State for Health, what assessment NHS England has made of the effectiveness of the Translarna drug in treating the limb girdle 2b form of Duchenne muscular dystrophy.
- Answer
-
NHS England has advised that limb girdle 2b is a form of muscular dystrophy distinct from Duchenne muscular dystrophy.
NHS England understands that Ataluren (Translarna) has not been trialed by the manufacturers of this drug, PTC Therapeutics, as a treatment for this disease and therefore no assessment has been made.
Secondary information
- Type
- Written question
- Reference
- 49849
- Session
- 2016-17
- Subjects
- Ataluren
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2022-08-19 12:59:05 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/49849
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/49849
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/49849